Trial Profile
A Phase II Evaluation of Temsirolimus (CCI-779) (NCI Supplied Agent: NSC# 683864,) in Combination With Carboplatin and Paclitaxel Followed by Temsirolimus Consolidation as First-Line Therapy in the Treatment of Clear Cell Carcinoma of the Ovary
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Oct 2022
Price :
$35
*
At a glance
- Drugs Temsirolimus (Primary) ; Carboplatin; Docetaxel; Paclitaxel
- Indications Carcinoma; Ovarian cancer
- Focus Therapeutic Use
- Acronyms GOG-0268
- 13 Oct 2022 Results estimating the 12-month progression-free survival (PFS) for carboplatin/paclitaxel plus temsirolimus in women with newly diagnosed clear cell ovarian cancer (CCOC), compared to historical controls in this patient population, published in the Gynecologic Oncology
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 23 Nov 2015 Status changed from active, no longer recruiting to completed as reported by clinicalTrials.gov record.